NextFin News - TPG Inc. has selected Malayan Banking Bhd. (Maybank) and UBS Group AG to advise on a potential exit from Asia OneHealthcare, a move that could value the Southeast Asian medical services provider at as much as 30 billion ringgit ($6.3 billion). The private equity firm is weighing a dual-track process, exploring both a direct sale and an initial public offering (IPO) for the Kuala Lumpur-based hospital operator, according to people familiar with the matter.
The appointment of advisers marks a formalization of TPG’s intent to monetize one of its most significant healthcare bets in the region. Asia OneHealthcare, which operates a network of hospitals including the prominent Sunway Medical Centre in Malaysia, has seen its valuation swell as regional demand for private healthcare outpaces public infrastructure. TPG initially partnered with the Sunway Group in 2021, acquiring a minority stake in its healthcare arm for approximately 750 million ringgit, a deal that valued the unit at roughly 4.7 billion ringgit at the time. The current targeted valuation of 30 billion ringgit represents a more than six-fold increase in enterprise value over five years, reflecting both aggressive expansion and a premium multiple for healthcare assets in emerging markets.
The decision to hire Maybank and UBS suggests a strategy aimed at capturing both local liquidity and international institutional interest. Maybank, Malaysia’s largest lender, provides the necessary domestic connectivity for a potential Bursa Malaysia listing, while UBS brings the global reach required for a cross-border trade sale or a high-profile international IPO. While a listing in Kuala Lumpur remains a strong possibility, the "sale or IPO" framing indicates that TPG is keeping its options open to maximize the exit multiple, potentially courting global healthcare conglomerates or rival private equity giants.
However, the ambitious $6.3 billion valuation is not without its skeptics. Some market participants suggest that such a figure—implying a high double-digit EBITDA multiple—may be difficult to achieve in a high-interest-rate environment where private equity buyers are increasingly disciplined. While healthcare is traditionally viewed as a defensive sector, the sheer scale of the deal could limit the pool of potential strategic acquirers. Furthermore, any IPO would need to navigate the volatility of Southeast Asian equity markets, which have seen mixed performance for large-scale listings over the past year.
The healthcare sector in Southeast Asia has become a primary battleground for private equity firms looking to capitalize on an aging population and a rising middle class. TPG’s move follows a broader trend of consolidation and exits in the space, as firms that invested during the mid-2010s and early 2020s reach the end of their fund cycles. The outcome of the Asia OneHealthcare process will serve as a critical barometer for the appetite of global investors for high-growth, high-valuation infrastructure in the region.
Explore more exclusive insights at nextfin.ai.
